Houston biotech firms’ trading halted over coronavirus-related claims

Securities trading for two Houston-based biotechnology firms is temporarily halted as the U.S. Securities and Exchange Commission questions recent claims made by the companies regarding Covid-19 treatments.

Moleculin Biotech Inc. (Nasdaq: MBRX) and CNS Pharmaceuticals Inc. (Nasdaq: CNSP) both had their trading temporarily halted by the SEC on May 1, the companies announced in separate May 4 press releases. The SEC temporarily suspended the biotech firms’ trading “because of questions regarding…